The Efficacy of vitamin D in treating patients with nasal congestion

Evaluation of vitamin D efficacy in the patients with Allergic rhinitis in comparison with control group

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20180217038763N2

Enrollment

Registered

2019-02-06

Start date

2018-05-22

Completion date

Unknown

Last updated

2019-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic rhinitis. Allergic rhinitis, unspecified

Interventions

Intervention 1: Intervention group: Routine treatment of allergic rhinitis include antihistamines with Perl D vitamin will be received for 8 weeks. Intervention 2: Control group: In the control group

Eligibility

Sex/Gender

All

Age

6 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients with allergic rhinitis Conscious Consent

Exclusion criteria

Exclusion criteria: Use of other drugs in addition to prescription drugs Having vitamin D deficiency Pregnant and infected people with immunodeficiency and skin diseases Having allergies to prescription drugs

Design outcomes

Primary

Measure	Time frame
Clinical symptoms of Allergic rhinitis. Timepoint: At the beginning of the study, and weeks 4 and 8, after starting taking vitamin D. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFereshteh Esmati nia

Mashhad University of Medical Sciences

f.esmatinia@yahoo.com+98 51 3841 3492

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026